Latest Current Report
Filed: 2026-01-12
Key Insights
- Vor Biopharma reported strong cash, cash equivalents and short-term investments of approximately $450 million as of December 31, 2025, indicating a robust financial position.
- The company will be presenting at the 44th Annual J.P. Morgan Healthcare Conference, providing an opportunity for investor engagement and visibility.
- The preliminary financial information is subject to change upon completion of the audited financial statements, suggesting investors should await the final results.